Search the Newsreel

T. Rowe Price Investment Management (MTSI) discloses 2.85M MACOM shares in 13G/A

T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 2,850,185 shares of MACOM Technology Solutions Holdings Inc. common stock, which represents 3.7% of the class. The firm reports sole voting power over 2,841,849 shares and sole …

Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $256.00 Price Target at Wells Fargo & Company

Wells Fargo & Company has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $316.00 to $256.00, while maintaining an "equal weight" rating. This adjustment implies a potential upside of 14.71% from the stock's previous close. Despite this reduction and similar moves by other …

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down on Disappointing Earnings

Semac Construction re-appoints Harivansh Dalmia as WTD for five years

Reminder - PennyMac Financial Services (PFSI) Goes Ex-Dividend Soon

Looking at the universe of stocks we cover at Dividend Channel, on 8/17/26, PennyMac Financial Services Inc (Symbol: PFSI) will trade ex-dividend, for its quarterly dividend of $0.30, payable on 8/27/26. As a percentage of PFSI's recent stock price of $79.21, this dividend works …

Intuitive Machines and Virgin Galactic Jump 10% While Rocket Lab, AST SpaceMobile Sit Out the Space Stock Rally

Quick Read LUNR surged 10% on record $1.8 billion backlog despite missing Q2 estimates, while SPCE bounced 10% after Thursday's 8% drop on a delayed launch. Stifel upgraded LUNR to Buy while Rocket Lab and AST SpaceMobile gained just 1%, confirming the space sector …

Armistice Capital (IRWD) discloses 13.9M-share Ironwood Pharmaceuticals stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 13,932,000 shares of Ironwood Pharmaceuticals, Inc.'s Class A common stock, which represents 8.43% of the outstanding class as of June 30, 2026. This stake is held by Armistice Capital Master Fund Ltd., …

Armistice Capital (RIGL) reports 1.67M Rigel Pharmaceuticals shares in 13G/A

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,672,000 shares of Rigel Pharmaceuticals (RIGL) common stock through a Schedule 13G/A filing. This represents 8.95% of the outstanding common stock as of June 30, 2026. The shares are held by Armistice Capital …

Quoin Q2 Loss Widens; Gets FDA's Conditional Nod For QYLEKI Brand Name For QRX003

(RTTNews) - Quoin Pharmaceuticals Ltd. (QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, reported second-quarter 2026 results and provided a corporate update highlighting progress across its QRX003 and QRX009 platforms. Quoin is developing topical therapies for rare dermatologic conditions, …

Eton Pharmaceuticals (NASDAQ:ETON) Sets New 1-Year High Following Earnings Beat

Eton Pharmaceuticals (NASDAQ:ETON) reached a new 52-week high after reporting strong Q2 earnings, with EPS of $0.43 and revenue of $37.59 million, significantly beating analyst estimates. The stock surged 42%, supported by a maintained "Buy" rating and increased price targets from analysts like HC …

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

CorMedix Therapeutics CRMD delivered second-quarter 2026 adjusted earnings of 29 cents per share, which increased 4% year over year from 28 cents reported in the year-ago quarter. The reported figure beat the Zacks Consensus Estimate of 26 cents. Consolidated revenues were $101.9 million, which …

Eton Pharmaceuticals stock hits all-time high at 55.07 USD

Eton Pharmaceuticals Inc. stock reached an all-time high of $55.07, currently trading at $54.43, significantly above its 52-week high. Despite appearing overvalued by InvestingPro analysis, the company has seen a 139.44% appreciation over the last year, with its market capitalization at $1.12 billion and …

Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting

Processa Pharmaceuticals shareholders approved several key proposals at their 2026 annual meeting on July 30, including an amendment to the 2019 Omnibus Incentive Plan to increase shares available for issuance by 200,000. Additionally, all six directors were re-elected, Cherry Bekaert, LLP was ratified as …

Intuitive Machines Posted Record Q2 Revenue – So, Why Is LUNR Stock Declining Today?

Space stock Intuitive Machines (NASDAQ: LUNR) tumbled 3% through 11:05 a.m. ET Thursday morning -- but it could have been worse. After reporting a big earnings miss for Q2 this morning, shares were at one point down as much as 16%! So what went …

Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is BioMarin Pharmaceutical (BMRN) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector …

Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants

Avoro Capital Advisors LLC and its controlling person Behzad Aghazadeh have disclosed a beneficial ownership of 9.64% in Arrowhead Pharmaceuticals (ARWR). This stake includes 13,823,383 shares of Common Stock, of which 2,467,828 shares are issuable upon the exercise of warrants. The investment firm holds …

Crinetics Pharmaceuticals merger with Vertex Pharmaceuticals advances after regulatory clearances

The proposed merger between Crinetics Pharmaceuticals (NASDAQ:CRNX) and Vertex Pharmaceuticals (NASDAQ:VRTX) has progressed after securing regulatory clearances, including the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period and approvals in Austria, Germany, and Australia. The acquisition, valued at approximately $10 billion, is expected …

Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Inc., Bloom Energy Corporation, Erasca, Inc., and Insulet Corporation. The investigations concern various allegations including misleading statements regarding product timelines, supply chain reliance, and manufacturing issues, which …

RIGL Maintained by HC Wainwright & Co. -- Price Target Raised to $85

HC Wainwright & Co. maintained a "Buy" rating for Rigel Pharmaceuticals (RIGL), increasing its price target from $57.00 to $85.00, reflecting confidence in the company's future growth. Despite this, Rigel Pharmaceuticals is currently priced at $42.10, which is 56.7% overvalued compared to its GF …

Stifel Highlights This ‘Important’ Factor For Intuitive Machines Despite Q2 Earnings Miss – LUNR Stock Heads For Fourth Straight Session Of Gains

Beijing Jingcheng Machinery Electric Declares No Mid‑Year Dividend in Unaudited 2026 Interim Results

Research Analysts Issue Forecasts for BCRX Q4 Earnings

Semac Construction consolidated net profit declines 51.43% in the June 2026 quarter

Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants

Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 4.9% in Tonix Pharmaceuticals Holding Corp., which includes 814,801 shares of common stock. This stake comprises 615,025 shares issuable upon the exercise of warrants. The ownership percentage is calculated based on …

Vertex to acquire Crinetics after HSR clearance; closing expected early Sept

Crinetics Pharmaceuticals announced that it has received HSR clearance for its merger with Vertex. The HSR waiting period expired on August 12, 2026, and antitrust approvals have also been secured in Austria, Germany, and Australia. The merger's closing is targeted for early September 2026, …

Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript

Crinetics Pharmaceuticals (CRNX) advances Vertex merger after key antitrust milestones

Crinetics Pharmaceuticals announced significant progress in its planned acquisition by Vertex Pharmaceuticals, with the Hart-Scott-Rodino waiting period expiring and antitrust approvals secured in Austria, Germany, and Australia. The merger's completion hinges on Crinetics shareholder approval at a meeting on August 28, 2026, with an …

Zacks Research Has Optimistic Outlook of WST Q3 Earnings

Zacks Research has updated its Q3 2026 earnings per share (EPS) estimate for West Pharmaceutical Services (NYSE: WST) to $2.14, maintaining a "Hold" rating. This optimistic outlook follows West Pharmaceutical's recent strong quarterly performance, where the company exceeded earnings and revenue expectations and raised …

What is HC Wainwright's Forecast for MIST Q3 Earnings?

No approved treatment for Peeling Skin Syndrome as Quoin plans Phase 2/3 study

Quoin Pharmaceuticals reported key pipeline milestones and its Q2 2026 financial results. The FDA granted conditional approval for QYLEKI™ as the proposed brand name for QRX003, intended for Netherton Syndrome, and cleared the first-ever IND for Peeling Skin Syndrome, enabling a Phase 2/3 study …

Deep Track Capital (XFOR) discloses 8.33% X4 Pharmaceuticals stake with capped warrants

Deep Track Capital and its affiliates have reported a beneficial ownership of 8.33% in X4 Pharmaceuticals (XFOR), totaling 8,040,894 shares with shared voting and dispositive power. This stake includes 2,162,137 Pre-Funded Warrants, which are subject to a 9.99% "Maximum Percentage" ownership cap, limiting their …

Ovarian cancer drug trial completes enrollment; PMV plans 2027 filing

PMV Pharmaceuticals reported Q2 2026 financial results and clinical progress for rezatapopt, including the completion of enrollment for the primary analysis in its Phase 2 PYNNACLE trial for platinum-resistant/refractory ovarian cancer. The company plans to submit a New Drug Application (NDA) for accelerated approval …

PMVP: Net loss narrowed, but liquidity concerns persist as rezatapopt advances toward NDA submission

PMV Pharmaceuticals (PMVP) reported a narrowed net loss of $18.1 million for Q2 2026, with $79.4 million in cash and equivalents. Despite progress with rezatapopt towards an NDA submission in early 2027, the company faces substantial doubt about its ability to continue operations without …

PMV Pharmaceuticals (PMVP) flags going-concern risk as rezatapopt advances toward NDA

PMV Pharmaceuticals reported a Q2 2026 net loss of $18.1 million and a first-half loss of $36.1 million, disclosing substantial doubt about its ability to continue as a going concern, as current cash resources are only expected to fund operations through Q2 2027. Despite …

Form 8K Pmv Pharmaceuticals Inc For: 14 August By Investing.com

This article from Investing.com announces the filing of a Form 8K by PMV Pharmaceuticals Inc. on August 14th. The brief piece includes the company's stock symbol PMVP and its real-time performance. The core content is minimal, serving primarily as a notification of the regulatory …